Sanford C. Bernstein upgraded shares of Coloplast A/S (OTCMKTS:CLPBY – Free Report) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.
Several other brokerages also recently commented on CLPBY. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res upgraded shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th.
Check Out Our Latest Research Report on Coloplast A/S
Coloplast A/S Price Performance
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.08 EPS for the quarter. The firm had revenue of $1.02 billion for the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. On average, equities research analysts forecast that Coloplast A/S will post 0.36 EPS for the current fiscal year.
Coloplast A/S Increases Dividend
The company also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were issued a dividend of $0.2435 per share. The ex-dividend date of this dividend was Monday, December 9th. This is a boost from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s dividend payout ratio (DPR) is currently 93.94%.
Coloplast A/S Company Profile
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.
Featured Articles
- Five stocks we like better than Coloplast A/S
- Why Invest in 5G? How to Invest in 5G Stocks
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Following Congress Stock Trades
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Consumer Staples Stocks, Explained
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.